US Patent

US7759308 — Microparticles comprising somatostatin analogues

Formulation · Assigned to Novartis AG · Expires 2026-10-25 · 0y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects microparticles containing a somatostatin analogue embedded in a biocompatible polymer matrix for long-acting release.

USPTO Abstract

Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.

Drugs covered by this patent

pasireotide-pamoate (PASIREOTIDE PAMOATE)

Patent Metadata

Patent number: US7759308
Jurisdiction: US
Classification: Formulation
Expires: 2026-10-25
Drug substance claim: No
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.